v3.26.1
Segment Reporting (Tables)
6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Summary of Disaggregated Amounts that Comprise Research and Development Expenses

In addition to the significant expense categories included within net loss presented on the statements of operations and comprehensive loss, see below for disaggregated amounts that comprise research and development expenses (in thousands):

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

External research and development expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Other external research and development (1)

 

$

2,565

 

 

$

(110

)

 

$

5,008

 

 

$

3,846

 

Consulting and outside services

 

 

907

 

 

 

317

 

 

 

1,655

 

 

 

954

 

Clinical trials expenses

 

 

620

 

 

 

368

 

 

 

1,374

 

 

 

895

 

Total external research and development expenses

 

 

4,092

 

 

 

575

 

 

 

8,037

 

 

 

5,695

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Internal research and development expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Personnel related expenses

 

 

1,927

 

 

 

2,625

 

 

 

4,725

 

 

 

5,195

 

Total research and development expenses

 

$

6,019

 

 

$

3,200

 

 

$

12,762

 

 

$

10,890

 

 

(1) Chemistry manufacturing controls, research and preclinical studies and other miscellaneous expenses.